The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.
Peptide degradation follows several routes. Hydrolysis cleaves the backbone at susceptible residues, oxidation targets methionine and tryptophan side chains, and aggregation produces higher-molecular-weight species that are difficult to reverse. Light exposure accelerates oxidation, which is why amber glass or opaque secondary packaging is common. Repeated freeze-thaw cycles promote aggregation and are best avoided. Stability-indicating methods detect these changes before they become visible.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
| Property | Value | Notes |
|---|---|---|
| Purity specification (research grade) | Greater than 95 percent by HPLC | Area percent at 220 nm; method dependent |
| Identity confirmation | Mass spectrometry | Observed mass compared with theoretical |
| Residual water | Reported by Karl Fischer titration | Affects peptide content calculation |
| Common synonyms | GLP-1 analog; GLP-1 receptor agonist peptide | Naming varies across catalogs |
| Container material | Low-binding polypropylene | Reduces adsorption at low concentration |
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
1993/1359) Fresh Meat and Poultry Meat (Hygiene, Inspection and Examinations for Residues) (Charges) (Amendment) Regulations 1993 (S.I. 1993/1360) Pneumoconiosis, Byssinosis and Miscellaneous Diseases Benefit (Amendment) Scheme 1993 (S.I. 1993/1363) Combined Probation Areas (Devon) Order 1993 (S.I. 1993/1364) Barnet, Camden and Westminster (London Borough Boundaries) Order 1993 (S.I. 1993/1365) Crop Residues (Burning) Regulations 1993 (S.I. 1993/1366) Local Government Superannuation (Local Commissioners) Regulations 1993 (S.I. 1993/1367) National Health Service (Fund-Holding Practices) (Scotland) Amendment Regulations 1993 (S.I. 1993/1369) Lancashire County Council (Proposed Connecting Roads to M6 Motorway at Haighton) Special Roads Scheme 1992 Confirmation Instrument 1993 (S.I. 1993/1370) A17 Trunk Road (Leadenham Bypass) Order 1993 (S.I. 1993/1371) A17 Trunk Road (Leadenham Bypass) (Detrunking) Order 1993 (S.I. 1993/1372) King's Lynn—Newark Trunk Road (Leadenham By-pass and Slip Roads) Order 1973 (Revocation) Order 1993 (S.I. 1993/1373) Registered Restrictive Trading Agreements (Inspection, Copy and Certification) (Fees) Regulations 1993 (S.I. 1993/1376) Greater London and Surrey (County and London Borough Boundaries) (No.4) Order 1993 (S.I. 1993/1391)
=== Function in other bacteria === Many bacteria, including Escherichia coli found in the large intestine, can synthesize vitamin K2 (MK-7 up to MK-11), but not vitamin K1. In the vitamin K2 (menaquinone)–synthesizing bacteria, menaquinone transfers two electrons between two different small molecules during oxygen-independent metabolic energy production processes (anaerobic respiration). For example, a small molecule with an excess of electrons (also called an electron donor) such as lactate, formate, or NADH, with the help of an enzyme, passes two electrons to menaquinone. The menaquinone, with the help of another enzyme, then transfers these two electrons to a suitable oxidant, such as fumarate or nitrate (also called an electron acceptor). Adding two electrons to fumarate or nitrate converts the molecule to succinate or nitrite plus water, respectively. Some of these reactions generate a cellular energy source, ATP, in a manner similar to eukaryotic cell aerobic respiration, except the final electron acceptor is not molecular oxygen, but fumarate or nitrate. In aerobic respiration, the final oxidant is molecular oxygen, which accepts four electrons from an electron donor such as NADH to be converted to water. E. coli, as facultative anaerobes, can carry out both aerobic respiration and menaquinone-mediated anaerobic respiration.
Driessen HP, de Jong WW, Tesser GI, Bloemendal H (1985). "The mechanism of N-terminal acetylation of proteins". CRC Crit. Rev. Biochem. 18 (4): 281–325. doi:10.3109/10409238509086784. PMID 3902358. Glembotski CC (1982). "Characterization of the peptide acetyltransferase activity in bovine and rat intermediate pituitaries responsible for the acetylation of beta-endorphin and alpha-melanotropin". J. Biol. Chem. 257 (17): 10501–9. doi:10.1016/S0021-9258(18)34046-8. PMID 6286657. O'Donohue TL (1983). "Identification of endorphin acetyltransferase in rat brain and pituitary gland". J. Biol. Chem. 258 (4): 2163–7. doi:10.1016/S0021-9258(18)32902-8. PMID 6296134. Tsunasawa S, Kamitani K, Narita K (February 1980). "Partial purification and properties of the amino-terminal amino acid-acetylating enzyme from hen's oviduct". J. Biochem. 87 (2): 645–50. doi:10.1093/oxfordjournals.jbchem.a132789. PMID 6244269.
For his contributions to the development and progress of Malaysia, Mahathir was honoured by his successor, Abdullah Badawi, with the title Bapa Pemodenan Malaysia (Father of Malaysia's Modernisation) after stepping down from office. The following year, Barisan Nasional leaders and members paid tribute to Mahathir during a dinner in Kuala Lumpur, acknowledging his remarkable contributions to the coalition and the nation.
== Legality == Plant breeding is subject to a different set of rules and regulations, at times contradictory. The International Union for the Protection of New Varieties of Plants (UPOV Convention) grants limited proprietary rights to breeders over their seeds, under certain conditions. In parallel, and often in a conflicting way, a series of dispositions aiming to fight against biopiracy require breeders to prove that the free, prior and informed consent was obtained from the communities (often Indigenous peoples or peasant communities) from where the seeds used to breed the new variety originates. This is the case in particular of the Nagoya Protocol, a treaty complementing the Convention on Biological Diversity, in force since 2014 (2017 in the European Union). In 2024, the GRATK Treaty was adopted, preventing national patent offices from granting patents based on biopiracy. Patent applicants relying on Cannabis strains will have to disclose the origin of the variety, which often entails compliance under the Nagoya protocol or other similar mechanisms of Access and Benefit Sharing Agreement.
Sources: en.wikipedia.org
enhancer RNA (eRNA) A subclass of long non-coding RNAs transcribed from regions of DNA containing enhancer sequences. The expression of a given eRNA generally correlates with the activity of the corresponding enhancer in enhancing transcription of its target genes, suggesting that eRNAs play an active role in gene regulation in cis or in trans.
==== Detection in body fluids ==== Morphine and its major metabolites, morphine-3-glucuronide, and morphine-6-glucuronide, can be detected in blood, plasma, hair, and urine using an immunoassay. Chromatography can be used to test for each of these substances individually. Some testing procedures hydrolyze metabolic products into morphine before the immunoassay, which must be considered when comparing morphine levels in separately published results. Morphine can also be isolated from whole blood samples by solid phase extraction (SPE) and detected using liquid chromatography-mass spectrometry (LC-MS). Ingestion of codeine or food containing poppy seeds can cause false positives. A 1999 review estimated that relatively low doses of heroin (which metabolizes immediately into morphine) are detectable by standard urine tests for 1–1.5 days after use. A 2009 review determined that, when the analyte is morphine and the limit of detection is 1 ng/ml, a 20 mg intravenous (IV) dose of morphine is detectable for 12–24 hours. A limit of detection of 0.6 ng/ml had similar results.
=== Hair loss === LLLT has been studied as a treatment for hair loss; a review in 2012 found little evidence to support the use of lasers to treat hair loss. A 2014 review found tentative evidence for benefit for lasers, while another 2014 review concluded that the results were mixed, had a high risk of bias, and that its effectiveness was unclear. A 2015 review found tentative evidence of benefit. Additionally, a 2017 review of clinical trials found 10 of 11 trials reviewed "demonstrated significant improvement of androgenic alopecia in comparison to baseline or controls when treated with LLLT." LLLT is shown to increase hair density and growth in both genders. The types of devices (hat, comb, helmet) and duration did not alter the effectiveness, with more emphasis to be placed on lasers compared to LEDs. Ultraviolet and infrared light are more effective for alopecia areata, while red light and infrared light is more effective for androgenetic alopecia. Medical reviews suggest that LLLT is as effective or potentially more than other non invasive and traditional therapies such as minoxidil and finasteride but further studies such as RCTs, long term follow up studies, and larger double blinded trials need to be conducted to confirm the initial findings.
== Mutations == Cone dystrophy (COD) is a retinal degradation of photoreceptor function wherein cone function is lost at the onset of the dystrophy but rod function is preserved until almost the end. COD has been linked to several genetic mutations including mutations in the guanylate cyclase activator 1A (GUCA1A) and guanylate cyclase 2D (GUY2D) among other enzymes. To be specific, GUY2D codes for RETGC-1, which is involved in cone adaptation and photoreceptor sensitivity by synthesizing cGMP. Low concentrations of calcium cause the dimerization of RETGC-1 proteins through stimulation from guanylate cyclase-activating proteins (GCAP). This process happens at amino acids 817-857, and mutations in this region increase RETGC-1 affinity for GCAP. This works to alter the calcium sensitivity of the neuron by allowing mutant RETGC-1 to be activated by GCAP at higher calcium levels than the wild-type. Because RETGC-1 produces cGMP, which keeps cyclic nucleotide-gated channels open allowing the influx of calcium, this mutation causes extremely high intracellular calcium levels. Calcium, which plays many roles in the cell and is tightly regulated, disrupts the membrane when it appears in excess. Also, calcium is linked to apoptosis by causing the release of cytochrome c. Therefore, mutations in the RETGC-1 can cause COD by increasing intracellular calcium levels and stimulating cone photoreceptor death.
Sources: en.wikipedia.org
Sealed, protected from light, and refrigerated at two to eight degrees Celsius for most research material. Desiccated storage limits moisture uptake. Allow the vial to reach room temperature before opening to prevent condensation.
Each cycle exposes the peptide to ice-liquid interfaces where unfolding and aggregation can occur. Aggregates may not redissolve and can alter measured activity. Aliquoting before the first freeze reduces the number of cycles any single portion experiences.
It usually reports purity by HPLC, identity by mass spectrometry, peptide content, appearance, and residual moisture or counterion content. The analytical method behind each value should be stated. Acceptance criteria are set by the supplier or the buyer's specification.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.